Subtopic Deep Dive
Intravitreal Bevacizumab for Retinopathy of Prematurity
Research Guide
What is Intravitreal Bevacizumab for Retinopathy of Prematurity?
Intravitreal bevacizumab injection treats stage 3+ retinopathy of prematurity (ROP) by inhibiting vascular endothelial growth factor (VEGF) to promote retinal vascularization as an alternative to laser therapy.
Clinical trials compare bevacizumab to laser for zone I and II ROP, showing superior efficacy in zone I disease (Mintz-Hittner et al., 2011, 1412 citations). Meta-analyses assess recurrence, long-term outcomes, and neurodevelopmental safety in preterm infants. Over 20 studies evaluate dosing and systemic effects.
Why It Matters
Bevacizumab reduces retinal destruction compared to laser, preserving peripheral vision in preterm infants with zone I stage 3+ ROP (Mintz-Hittner et al., 2011). It lowers recurrence rates in severe cases with poor mydriasis (Higashiyama et al., 2017). Neurodevelopmental studies address systemic VEGF inhibition risks (Morin et al., 2016), guiding treatment for thousands of annual ROP cases worldwide. Cochrane reviews highlight needs for long-term data (Sankar et al., 2018).
Key Research Challenges
Recurrence After Treatment
Bevacizumab delays but risks late reactivation of ROP due to VEGF rebound (Mintz-Hittner et al., 2011). Zone II cases show no benefit over laser, increasing recurrence (Hwang et al., 2015). Monitoring protocols remain inconsistent across studies.
Systemic Neurodevelopmental Risks
VEGF inhibition may affect brain development via systemic absorption in preterm infants (Morin et al., 2016). Long-term cognitive outcomes require extended follow-up beyond current trials. Balancing ocular benefits against potential delays is unresolved.
Optimal Dosing Protocols
Standard 0.625 mg doses lack optimization for infant weight and ROP zone (Mintz-Hittner and Kuffel, 2008). Comparisons to ranibizumab or aflibercept are limited. Personalized regimens need randomized trials.
Essential Papers
Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity
Helen A. Mintz-Hittner, Kathleen A. Kennedy, Alice Z. Chuang · 2011 · New England Journal of Medicine · 1.4K citations
Intravitreal bevacizumab monotherapy, as compared with conventional laser therapy, in infants with stage 3+ retinopathy of prematurity showed a significant benefit for zone I but not zone II diseas...
Automated Diagnosis of Plus Disease in Retinopathy of Prematurity Using Deep Convolutional Neural Networks
James M. Brown, J. Peter Campbell, Andrew Beers et al. · 2018 · JAMA Ophthalmology · 629 citations
This fully automated algorithm diagnosed plus disease in ROP with comparable or better accuracy than human experts. This has potential applications in disease detection, monitoring, and prognosis i...
Usefulness of Intravitreal Bevacizumab for Retinopathy of Prematurity with Severely Dilated Tunica Vasculosa Lentis and Poor Mydriasis
Tomoaki Higashiyama, Sanae Muraki, Masahito Ohji · 2017 · Case Reports in Ophthalmology · 449 citations
<b><i>Background:</i></b> Laser therapy has been the gold standard treatment for retinopathy of prematurity (ROP), while intravitreal bevacizumab (IVB) is reported to be of ...
Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity
Julie Morin, Thuy Mai Luu, Rosanne Superstein et al. · 2016 · PEDIATRICS · 283 citations
BACKGROUND AND OBJECTIVE: Bevacizumab intravitreal injection, a vascular endothelial growth factor inhibitor, is used to treat retinopathy of prematurity (ROP). However, concerns have been raised r...
Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life
Przemysław Sapieha, Jean‐Sébastien Joyal, José Carlos Rivera et al. · 2010 · Journal of Clinical Investigation · 266 citations
Retinopathy of prematurity (ROP) is a major complication of preterm birth. It encompasses a spectrum of pathologies that affect vision, from mild disease that resolves spontaneously to severe disea...
Ophthalmic Drug Delivery Systems for the Treatment of Retinal Diseases: Basic Research to Clinical Applications
Henry F. Edelhauser, Cheryl L. Rowe-Rendleman, Michael R. Robinson et al. · 2010 · Investigative Ophthalmology & Visual Science · 253 citations
the National Institutes of Health (NIH) in Bethesda, Maryland.The conference provided an opportunity to gather a diverse group of more than 200 experts from both academic ophthalmology and the opht...
IL-1 Family Members Mediate Cell Death, Inflammation and Angiogenesis in Retinal Degenerative Diseases
Yvette Wooff, Si Ming Man, Riemke Aggio‐Bruce et al. · 2019 · Frontiers in Immunology · 251 citations
Inflammation underpins and contributes to the pathogenesis of many retinal degenerative diseases. The recruitment and activation of both resident microglia and recruited macrophages, as well as the...
Reading Guide
Foundational Papers
Start with Mintz-Hittner et al. (2011, 1412 citations) for BEAT-ROP trial efficacy in zone I; Mintz-Hittner and Kuffel (2008, 246 citations) for initial safety data; Sapieha et al. (2010) for ROP pathophysiology context.
Recent Advances
Morin et al. (2016) for neurodevelopmental outcomes; Sankar et al. (2018) Cochrane for anti-VEGF synthesis; Higashiyama et al. (2017) for niche applications like poor mydriasis.
Core Methods
Intravitreal 0.625 mg injection vs. panretinal laser photocoagulation; outcomes via zone progression, recurrence rates, visual acuity; VEGF inhibition measured by vascular regression (Mintz-Hittner et al., 2011).
How PapersFlow Helps You Research Intravitreal Bevacizumab for Retinopathy of Prematurity
Discover & Search
Research Agent uses searchPapers and exaSearch to find trials like 'Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity' (Mintz-Hittner et al., 2011). citationGraph reveals 1412 citations and clusters zone I efficacy studies. findSimilarPapers identifies meta-analyses like Sankar et al. (2018).
Analyze & Verify
Analysis Agent applies readPaperContent to extract recurrence rates from Mintz-Hittner et al. (2011), then verifyResponse with CoVe checks claims against Morin et al. (2016) neurodata. runPythonAnalysis performs GRADE grading on 10+ trials and meta-regression of hazard ratios for zone-specific outcomes. Statistical verification confirms laser vs. bevacizumab effect sizes.
Synthesize & Write
Synthesis Agent detects gaps in long-term neurodevelopmental data via gap detection and flags contradictions between early (Mintz-Hittner and Kuffel, 2008) and later studies (Morin et al., 2016). Writing Agent uses latexEditText for trial comparison tables, latexSyncCitations for 20-paper bibliographies, and latexCompile for submission-ready reviews. exportMermaid visualizes treatment outcome flowcharts.
Use Cases
"Compare recurrence rates of bevacizumab vs laser in zone I ROP using meta-analysis data."
Research Agent → searchPapers + citationGraph → Analysis Agent → runPythonAnalysis (pandas meta-regression on HRs from 5 trials) → outputs forest plot CSV and GRADE-scored summary.
"Draft a review section on bevacizumab safety with citations from Mintz-Hittner 2011 and Morin 2016."
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations + latexCompile → outputs LaTeX manuscript chunk with formatted references and figure.
"Find code for automated ROP plus disease diagnosis linked to bevacizumab timing."
Research Agent → paperExtractUrls on Brown et al. (2018) → Code Discovery → paperFindGithubRepo + githubRepoInspect → outputs CNN model repo for integrating with treatment outcome predictors.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ bevacizumab-ROP papers: searchPapers → citationGraph → DeepScan 7-step analysis with GRADE checkpoints → structured report on efficacy/recurrence. DeepScan verifies neurodevelopmental claims: readPaperContent (Morin et al., 2016) → CoVe → runPythonAnalysis survival curves. Theorizer generates hypotheses on optimal dosing from Mintz-Hittner (2011) and Sankar (2018) patterns.
Frequently Asked Questions
What defines intravitreal bevacizumab for ROP?
Intravitreal injection of 0.625 mg bevacizumab treats stage 3+ ROP by blocking VEGF to regress neovascularization, especially in zone I (Mintz-Hittner et al., 2011).
What methods compare bevacizumab to laser?
Randomized trials like BEAT-ROP use monotherapy vs. laser photocoagulation, measuring progression to retinal detachment (Mintz-Hittner et al., 2011). Meta-analyses pool recurrence hazards (Sankar et al., 2018).
What are key papers?
Mintz-Hittner et al. (2011, 1412 citations) shows zone I superiority; Morin et al. (2016) assesses neurodevelopment; Sankar et al. (2018) Cochrane review summarizes anti-VEGF evidence.
What open problems exist?
Long-term retinal function, neurodevelopmental impacts, and optimal dosing need multi-year RCTs (Morin et al., 2016; Sankar et al., 2018). Reactivation risks post-bevacizumab persist.
Research Retinopathy of Prematurity Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Intravitreal Bevacizumab for Retinopathy of Prematurity with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers